Alkahest reported that Helen Jenkins has joined the company's executive team as Chief Operating Officer. In this role, Jenkins will be responsible for translating corporate business priorities into operational tactics that achieve Alkahest's financial and strategic goals. Jenkins joins Alkahest from Tobira Therapeutics, where she served as Chief Operating Officer, and played a key role in Tobira's acquisition by Allergan plc in a deal valued at up to $1.7 billion in November of 2016.